[{"address1": "8-2, Kyutaromachi 1-chome", "address2": "Chuo-ku", "city": "Osaka", "zip": "541-8564", "country": "Japan", "phone": "81 6 6263 5670", "website": "https://www.ono-pharma.com", "industry": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.", "fullTimeEmployees": 3853, "companyOfficers": [{"maxAge": 1, "name": "Mr. Gyo  Sagara", "age": 65, "title": "CEO & Chairman of the Board", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 986048, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Toichi  Takino Ph.D.", "age": 55, "title": "President, COO & Representative Director", "yearBorn": 1968, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Masaki  Ito", "title": "Corp. Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., Fin. & Acc. Dept. and Corp. Tax", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Takehiro  Yamada", "title": "Corporate Officer & Head of Risk and Compliance Management Department", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Satoshi  Takahagi", "title": "Managing Executive Officer, Head of Sales Division & Head of Primary Department", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Masayuki  Tanigawa", "title": "Corporate Officer & Head of Business Strategy Headquarters", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Toshihiro  Tsujinaka", "age": 59, "title": "Ex. EO, Executive Dir. of Sus. Promotion Corp. Strategy & Planning and Representative Director", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Hiromu  Habashita Ph.D.", "title": "Corporate Officer & Deputy Executive Director, Discovery & Research", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Shinji  Takai M.D., Ph.D.", "title": "Corporate Officer & Head of Medical Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Akira  Takada", "title": "Managing Executive Officer & CMC / Production Division Chief", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 3, "compensationRisk": 1, "shareHolderRightsRisk": 2, "overallRisk": 2, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 2, "previousClose": 16.12, "open": 16.12, "dayLow": 16.12, "dayHigh": 16.12, "regularMarketPreviousClose": 16.12, "regularMarketOpen": 16.12, "regularMarketDayLow": 16.12, "regularMarketDayHigh": 16.12, "dividendRate": 0.52, "dividendYield": 0.0387, "exDividendDate": 1727395200, "payoutRatio": 0.3147, "trailingPE": 7.723121, "forwardPE": 10.951639, "volume": 9, "regularMarketVolume": 9, "averageVolume": 357, "averageVolume10days": 30, "averageDailyVolume10Day": 30, "bid": 13.0, "ask": 15.98, "bidSize": 28000, "askSize": 42300, "marketCap": 6724618240, "fiftyTwoWeekLow": 13.361, "fiftyTwoWeekHigh": 16.12, "priceToSalesTrailing12Months": 0.013440339, "fiftyDayAverage": 14.131714, "twoHundredDayAverage": 14.131714, "trailingAnnualDividendRate": 80.0, "trailingAnnualDividendYield": 4.962779, "currency": "USD", "enterpriseValue": 23645923328, "sharesOutstanding": 469647008, "heldPercentInsiders": 0.15546, "heldPercentInstitutions": 0.43887, "bookValue": 1726.264, "priceToBook": 0.007739836, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": 120953004032, "trailingEps": 1.73, "forwardEps": 1.22, "pegRatio": -160089.0, "enterpriseToRevenue": 0.047, "enterpriseToEbitda": 0.141, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "OPHLF", "underlyingSymbol": "OPHLF", "shortName": "Ono Pharmaceutical Co., Ltd.", "longName": "Ono Pharmaceutical Co., Ltd.", "firstTradeDateEpochUtc": 1723728600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2fc3c55a-9df3-3ac1-8e51-85bbc68455d4", "gmtOffSetMilliseconds": -14400000, "currentPrice": 13.361, "recommendationKey": "none", "totalCash": 150918004736, "totalCashPerShare": 321.345, "ebitda": 167624998912, "totalDebt": 162607005696, "quickRatio": 1.192, "currentRatio": 1.532, "totalRevenue": 500330987520, "debtToEquity": 19.917, "revenuePerShare": 1052.582, "returnOnAssets": 0.095649995, "returnOnEquity": 0.15277, "freeCashflow": 135747502080, "operatingCashflow": 121111003136, "operatingMargins": 0.26079, "financialCurrency": "JPY", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]